Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension

This phase 2 trial evaluated the efficacy and safety of baxdrostat, a selective aldosterone synthase inhibitor, in patients with treatment-resistant hypertension. The multicenter, randomized, placebo controlled study included 275 patients receiving stable doses of at least three antihypertensive medications. Results showed dose dependent reductions in systolic blood pressure, with the 2mg dose group achieving a significant decrease of 11.0 mm Hg compared to placebo. Baxdrostat also reduced serum aldosterone levels without affecting cortisol synthesis. Adverse events were mild, with hyperkalemia occurring in a small subset of patients. The findings suggest baxdrostat as a promising therapeutic option for treatment resistant hypertension, warranting further investigation in phase 3 trials.

This phase 2 trial evaluated the efficacy and safety of baxdrostat, a selective aldosterone synthase inhibitor, in patients with treatment-resistant hypertension. The multicenter, randomized, placebo controlled study included 275 patients receiving stable doses of at least three antihypertensive medications. Results showed dose dependent reductions in systolic blood pressure, with the 2mg dose group achieving a significant decrease of 11.0 mm Hg compared to placebo. Baxdrostat also reduced serum aldosterone levels without affecting cortisol synthesis. Adverse events were mild, with hyperkalemia occurring in a small subset of patients. The findings suggest baxdrostat as a promising therapeutic option for treatment resistant hypertension, warranting further investigation in phase 3 trials.